We are Polyplus

Who we are

Polyplus, part of Sartorius, is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale.

An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services for viral and non-viral delivery. Custom plasmid vector design and plasmid and protein manufacturing was integrated into the offer in 2022 to expand the products and services portfolio to help the industry optimize process economics while meeting strict scientific and regulatory standards.

Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia. Since July 2023, Polyplus is now part of Sartorius.

Our mission

Our mission is to develop innovative solutions that enable scientists to develop breakthrough nucleic acid-based therapies that improve human health.

Founding the company

Polyplus has been driven to innovate solutions for nucleic acid delivery that power your science since January 2001. Originally named Polyplus-transfection, the company shortened the name to Polyplus in 2022, as we began to expand our focus on building our portfolio of purpose fit solutions and services that help customers optimize upstream process economics.

Read more

Our Vision

Our vision is to help drug developers and manufacturers innovate with greater confidence and quality while reducing cost and time to market for cell and gene therapies and RNA & DNA therapeutics.


Our Company Values


Growing profitably and acting responsibly towards all stakeholders


Driving change and progress internally and externally


Working in an energetic and rewarding environment

Our Management Team

Mario Philips
Chairman & CEO 

Mario Philips draws on more than 20 years of scientific expertise, technical innovation, and operational management to lead the team in his role as CEO & Chairman at Polyplus. He has been an active industry advocate throughout his career, driving a great deal of progress in the single use space, and is now leading the charge to optimize upstream process economics for today’s advanced modalities.

Patrick Erbacher, Ph.D.
Chief Scientific Officer

Patrick Erbacher (Ph.D.) is a legacy Polyplus employee who joined as a postdoctoral research scientist working in founder, Dr. Behr’s, laboratory of genetic chemistry. During his time at the company, he has invaluably driven scientific strategy, and is a frequent author and inventor with 12 co-authored patent applications and more than 35 scientific publications.

Roel Gordijn
Chief Commercial Officer

Roel Gordijn has deep expertise in global commercial structure and operations in this evolving industry. He is responsible for building and driving commercial activity with a focus on what the customer is facing while working to accommodate the growing list of modalities in the market.

Chantal Devin-Chaloin, Ph.D.
Director Global Operations & Supply Chain 

Chantal Devin-Chaloin (Ph.D.) joined the company with the goal of expanding and securing the global supply chain for Polyplus, customers and partners. She pulls from operations management experience in the contract space to help refine the go to market strategy and customer experience.

Stéphane Béchot
Chief Finance Officer

Stéphane Béchot joined Polyplus to manage Finance, Administration, IT. His expertise in Financial Consulting, Food industry, Engineering and IT Services have been a great resource to keep the company running efficiently.

Our Corporate Social Responsibility


Responsible waste management

We consider our impact on the environment in the footprint of our facilities, how they are operated and the waste produced. New construction is focused on leveraging sustainable resources and minimizing wasteful output. All facilities have functional hazardous waste recovered as energy and non-hazardous waste recycled as materials.


Responsible use of resources

Our sustainability efforts are integrated into daily operations, including eco-friendly behavior training to align with our waste initiatives. We follow government energy-saving guidelines by setting temperatures to 19C in winter and 26C in summer. And decarbonated energy from predominantly nuclear resources powers our facilities.


Responsible jobs provider

It is our responsibility as an employer to offer quality jobs that empower individuals AND the communities we are located in. We prioritize making positive long-term impacts with sustainable design and leveraging alternative energy sources. As business models change, we are also decreasing our footprint in transportation, and via hybrid working models.

Research & Development

Based on its core know-how in the field of nucleic acid engineering and delivery technology, Polyplus ®’s R&D team is focused on developing innovative products for the upstream manufacturing of biologics for advanced medicinal therapy and for the development of nucleic acid-based therapeutics. Our R&D is optimizing key critical components of the manufacturing workflow (plasmids, media, transfection reagents) to increase viral vector titers and quality. Our R&D team is developing also critical materials (plasmids, lipids, polymers) and nanoparticle solutions for novel non-viral RNA/DNA therapeutics. 

Explore Our R&D

Team Leader Développement

Join our team

Add value to Human life, where our mission is to develop cutting-edge delivery technologies to enable scientists to develop breakthrough nucleic acid-based therapies as treatment to improve Human health every step of the way from basic science to the clinic.

Explore our Careers

Over 100 partners & distributors

Believe in us

  • sartorius logo
  • Allergan Logo
  • logo cellvec
  • logo corning
  • finnvector logo
  • Genethon Logo
  • Molmed logo
  • logo pieris
  • trenzyme logo
  • Vigene Logo
  • vivebiotech logo

Explore Polyplus

What is Transfection

Quality Management

Licensing Opportunities

Patents and Trademarks

Scientific Support Specialists

Stork Story